Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

Eli Lilly (LLY) is positioned as the “easy choice” for 2026, supported by FY2025 results of ~$65.2B revenue (+44% YoY) and ~$20.6B net income (about 2x 2024), alongside strong free cash flow near $9B. Despite higher leverage (debt-to-equity ~1.6x) and regulatory risks from the Inflation Reduction Act, LLY trades at a higher valuation (Forward P/E 33.1x vs Teva’s 16.4x; P/S 15.2x vs 2.3x). Teva (TEVA) shows stabilization with FY2025 revenue near $17.3B (+~4% YoY), ~$1.4B net income (~8.2% margin) and ~$1.2B free cash flow, but remains more levered (debt-to-equity ~2.2x) with continued generic price-pressure risks. Market impact is likely limited as this is primarily a comparative valuation/growth outlook rather than a fresh earnings or policy shock.

Analysis

LLY is still the cleaner quality-growth asset, but the market is paying today for a multi-year obesity franchise that is already becoming a consensus position. The key second-order issue is not just unit growth; it is whether payer pressure, IRA pricing, and competitive launch cadence slowly compress realized net price faster than the Street is modeling. If execution stays near current pace, the upside likely shifts from multiple expansion to earnings compounding, which argues for using pullbacks or structures rather than chasing the stock outright.

TEVA is less a 2026 growth story than a balance-sheet repair story with optionality attached. In a higher-rate world, leverage matters more than headline valuation because refinancing flexibility and legal overhang can absorb much of the operating upside; a few hundred basis points of spread widening would matter more than a modest beat on revenue. The contrarian take is that the market may be underestimating how durable specialty/generic cash flow can be, but it still looks like a range-trading equity until debt keeps coming down and product mix proves it can offset generic erosion.

The better unintended beneficiaries are the distributors, not the drugmakers: MCK, COR, and CAH should capture volume growth with far less binary patent risk. That said, distribution is a spread business, so the upside is incremental rather than transformative; this is a relative-value setup, not a deep fundamental rerating. NVO remains the most obvious loser if obesity share keeps tilting to LLY, but the real thesis break would be a faster-than-expected normalization in GLP-1 supply or a major price/coverage reset that hits all players at once.

Key Decisions for Investors

• Long LLY on 3-6 month pullbacks only; avoid paying peak enthusiasm. Use it as a quality-growth hold, but size modestly because the stock already discounts a strong 2026 trajectory. Falsifier: any guide-down in obesity growth or evidence of net pricing compression.
• Pair trade: long LLY / short NVO for 3-12 months. The relative thesis is that share and pipeline expectations remain biased toward Lilly while Novo faces more multiple compression if launch cadence slips. Exit if NVO shows sustained U.S. volume acceleration or LLY supply constraints re-emerge.
• Long the pharma-distribution basket MCK/COR/CAH vs short XBI over 1-3 months. This captures the volume windfall from GLP-1 and specialty-drug throughput with materially less clinical/regulatory risk than owning the drug developers directly.
• Avoid initiating a new long TEVA equity position purely on valuation; if you want exposure, prefer a small tactical trade only after management proves debt reduction and FCF conversion in the next 1-2 quarters. The equity remains a levered call on execution, not a clean value story.
• Set a watch item on TEVA credit spreads and refinancing commentary over the next 6-12 months. If spreads tighten and net debt trends down faster than expected, the stock could rerate sharply; if not, the low P/E is likely a value trap.